StageZero Life Sciences Partners with DiagnoseAtHome to Offer Aristotle(R) Multi-Cancer Blood Test in Canada and USA
First-ever mRNA gene expression, multi-cancer panel simultaneously screens for multiple cancers from a single sample of bloodTORONTO, ON and RICHMOND, VA / ACCESSWIRE / May 25, 2022 / StageZero Life Sciences, Ltd. (TSX:SZLS) (OTCQB:SZLSF) …
First-ever mRNA gene expression, multi-cancer panel simultaneously screens for multiple cancers from a single sample of blood
TORONTO, ON and RICHMOND, VA / ACCESSWIRE / May 25, 2022 / StageZero Life Sciences, Ltd. (TSX:SZLS) (OTCQB:SZLSF) ("StageZero" or the "Company"), a vertically integrated healthcare company devoted to improving the early detection and management of cancer and other chronic diseases through leading-edge molecular diagnostics and clinical interventions, today announced that it has partnered with DiagnoseAtHome ("DAH") to make the Company's multi-cancer blood test, Aristotle®, available to DiagnoseAtHome's patients in Canada and the USA. Built on StageZero's proprietary mRNA gene expression technology platform, Aristotle is a next-generation test which simultaneously screens for multiple cancers from a single sample of blood.
DiagnoseAtHome offers accessible at-home health and lab testing solutions, allowing businesses, organizations, and healthcare providers to offer safe, accurate and discreet lab testing to patients as an alternative to in-person laboratory visits. Powered by a proprietary technology platform, DAH partners with telehealth organizations, assisted living, long-term care facilities, corporations, self-insured employers, healthcare providers, and clinics.
"Our partnership with DiagnoseAtHome allows greater access to early cancer screening for their many clients and broadens the availability of Aristotle® in Canada and the USA," said James Howard-Tripp, Chairman and CEO of StageZero Life Sciences. "Growing our patient base and expanding the availability of our early cancer test is a key pillar in our Growth Strategy. We look forward to working with DiagnoseAtHome and their patients and clients."
""Our partnership with StageZero Life Sciences furthers our mission to provide accessible cutting edge diagnostic solutions to patients and providers at scale" said Dr Ian Plener, founder of DiagnoseAtHome. By onboarding Aristotle to the DAH platform, we are better able to provide our patients and providers with a novel approach to early cancer screening. Growing our laboratory network will further enhance the breadth of curated laboratory solutions available to our growing patient and provider base. We look forward to working with the entire StageZero Life Sciences team."